| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5826182 | Current Opinion in Pharmacology | 2012 | 4 Pages |
Abstract
⺠Single therapy with LAMAs, LABAs or ICS often fail to control symptoms in chronic obstructive pulmonary disease (COPD). ⺠Increasing evidence supports the use of two or all three drug classes in COPD. ⺠Combination inhalers improve compliance and evaluation of efficacy and safety. ⺠Several novel molecules are being developed for once daily combination treatment. ⺠Better phenotyping of COPD is likely to improve individualization of treatment.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Anders Bjerg, Bo Lundbäck, Jan Lötvall,